Abstract 1644P
Background
Pancreatic ductal adenocarcinoma (PDAC) has been found to metastasize in more than 50% of patients at the time of their initial diagnosis. This is considered to be the main reason for mortality. The liver and peritoneum are frequently observed as metastatic locations in cases of PDAC. The mutational profile and evolutionary patterns of metastatic lesions in the liver and peritoneum in pancreatic cancer remain poorly understood.
Methods
Whole exome sequencing (WES) was performed on 47 samples from 30 treatment-naïve, synchronously resected hepatic or peritoneal metastatic PDACs. The present study examined 10 primary tumours that did not metastasize within a year after surgery (non-PTs), 8 matched pairs of liver-metastatic primary (LiM-PTs) and metastatic (LiM-MTs), 9 matched pairs of peritoneal-metastatic primary (PeM-PTs), and 3 unpaired primary and metastatic tumours.
Results
KRAS mutations were found in 89.65% (26/29) of primary tumours, 70% (7/10) of liver metastases, and 100% (8/8) of peritoneal metastases. Interestingly, PCDHB14 and PXDN mutations were only detected in non-PTs, MUC16 were only detected in LiM-PTs, and ZNF594 were only detected in PeM-PTs, although there was no statistical difference. Meanwhile, the LiM-MTs group had higher TMB than PeM-MTs group (P=0.048). Mutation pattern analysis found that transitions outnumbered transversions in all samples. The paired LiM-PTs and PeM-PTs samples underwent GO and KEGG analyses. The ECM-receptor interaction signaling pathway that has been linked to metastasis in other cancer types was found to be distinct in LiM-PTs as compared to other groups. On the other hand, the proteoglycans and calcium signaling pathway was found to be unique to LiM-MTs when compared to PeM-MTs. Phylogenetic relationships analysis found that neither the LiM group nor the PeM group has a unified evolutionary pattern.
Conclusions
This research reveals that PDAC liver metastasis and peritoneal metastasis differ in mutated genes and evolutionary pattern. These results suggest that different biological mechanisms may exist in metastasis to different sites, and also highlights the need for more precise personalized treatment for PDAC in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The first affiliated hospital of Henan university of science and technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22